arrow
D

Damien Kee

Peter MacCallum Cancer Centre
H指数:24
被引数:4,743

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

在GNAQ/GNA11突变型黑色素瘤中具有Gq/11抑制剂载荷的抗PMEL抗体−药物偶联物:一项1期临床试验

2026-07-130
OA
The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma
2024-10-010
PRE
Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study

纳武利尤单抗和伊匹木单抗联合治疗晚期dMMR/MSI-H非结直肠癌:MoST-CIRCUIT II期研究的结果

2024-09-010
PRE
Targeting homologous recombination deficiency in uterine leiomyosarcoma

靶向子宫平滑肌肉瘤的同源重组缺陷

2023-05-0410
OAAI
EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma

EWSR1-BEND2融合定义了星形细胞瘤的表观遗传学独特亚型

2021-11-2524
OAAI
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

在braf-mek抑制剂上进展的黑色素瘤脑转移证明对ipilimumab-nivolumab的耐药性与先天PD-1耐药特征 (IPRES) 相关

2021-10-0820
OAAI
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
2021-07-2860
OA